Middle East Pharmaceutical Industries Company SJSC TADAWUL:4016:
AVALON PHARMA - CONTRACT SIGN OFF WITH BIO-THERA SOLUTIONS
AVALON PHARMA - CONTRACT VALUE REPRESENTS ABOVE 5% OF CO’S REVENUES
AVALON PHARMA - 2030 ONWARDS, ESTIMATING INCREMENTAL REVENUE OF AT LEAST 500 MN SAR DURING CONTRACT PERIOD
AVALON PHARMA- CONTRACT FOR EXCLUSIVE LICENSE TO REGISTER ,COMMERCIALIZE PEMBROLIZUMAB IN SAUDI, MENA MARKETS